17 research outputs found
The Dynamics of Signaling as a Pharmacological Target
SummaryHighly networked signaling hubs are often associated with disease, but targeting them pharmacologically has largely been unsuccessful in the clinic because of their functional pleiotropy. Motivated by the hypothesis that a dynamic signaling code confers functional specificity, we investigated whether dynamic features may be targeted pharmacologically to achieve therapeutic specificity. With a virtual screen, we identified combinations of signaling hub topologies and dynamic signal profiles that are amenable to selective inhibition. Mathematical analysis revealed principles that may guide stimulus-specific inhibition of signaling hubs, even in the absence of detailed mathematical models. Using the NFÎşB signaling module as a test bed, we identified perturbations that selectively affect the response to cytokines or pathogen components. Together, our results demonstrate that the dynamics of signaling may serve as a pharmacological target, and we reveal principles that delineate the opportunities and constraints of developing stimulus-specific therapeutic agents aimed at pleiotropic signaling hubs
Temporal encoding and homeostatic control in the IKK- kappaNF-kappaB signaling system
The transcription factor NF-kappaB is part of a signaling system that interprets a variety of physiological stimuli. NF-kappaB regulates numerous genes that play important roles in inter- and intracellular signaling, cellular stress responses, cell growth, survival, and apoptosis. This dissertation is an examination of the hypothesis that dynamic control of NF-kappaB is key to understanding the processing that allows these specific responses. This study investigates the existence, mechanisms, and implications of temporal coding within the IKK-IkappaB-NF- kappaB system. The starting point of this work is a previously published, biochemically detailed ordinary differential equation model of NF-kappaB signaling whose predictions for dynamic responses to a single stimuli (TNF) corresponded with experiments. I extend this model in a number of ways. First, I refine its parameters and reaction list. Doing so allows me to improve the model's equilibrium predictions for resting cells. It also leads me to highlight the importance of a second degradation pathway (IKK independent free IkappaB degradation) for steady-state regulation, in addition to IKK induced degradation of complexed IkappaB. Second, I apply three additional computational techniques to investigate its signal processing characteristics. Clustering allows me to gain insight into the temporal encoding of IKK, such as the lesser importance of early IKK plateaus and greater impact (and fine-grained regulation) of later IKK plateaus. Information theory guides the design and testing of a mutant cell which loses the ability to distinguish stimuli that are distinguished by wild type cells. Principal component analysis allows me to identify common mechanisms whose alterations have stimulus specific effects, altering the responses to some stimuli much more strongly than others. Third, I test and validate its utility against a much wider range of experiments. Using the experimental work of my collaborators, I am able to link simulations to experiments for multiple stimuli, with genetic and pharmacological interventions, and with multiple doses and timings. In conclusion, this dissertation breaks new ground in using simulations and experiments to understand temporal control in a cell signaling system of great scientific interest, and develops techniques which have relevance for other efforts to understand cell signalin
M1086 Prediction of Inflammatory Bowel Disease (IBD) Using Serological Testing: A Retrospective Study of Serologic Marker and Diagnostic Prediction Consistency in Repeated Test Results
M1100 Prediction of Inflammatory Bowel Disease (IBD) Using Serological Testing: Results from a Multi-Center Clinical Study
357 Serum Immune Responses to Anti-CBIR1 Flagellin (CBIR1) Correlates with HLA DQA1*05-DQB1*0201 (DQ2.5) and DQA1*03-DQB1*0302 (DQ8) in a Large Group of U.S. Patients At-Risk for Celiac Disease (N=5406) Who Are Ema Positive
Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.
BackgroundThe relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated.MethodsPer protocol, at baseline all SLE subjects enrolled in this longitudinal study presented with active disease and elevated CB-CAPs. At each monthly visit, the non-serological (ns) Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA-SLEDAI) and the British Isles Lupus Assessment Group (BILAG)-2004 index scores were determined as was a random urinary protein to creatinine ratio (uPCR). Short-form 36 (SF-36) questionnaires were also collected. All soluble markers were determined using immunoassays, while EC4d and EC3d were determined using flow cytometry. Statistical analysis consisted of linear mixed models with random intercept and fixed slopes.ResultsA total of 36 SLE subjects (mean age 34 years; 94% female) were enrolled and evaluated monthly for an average 11 visits per subject. Clinical improvements were observed during the study, with significant decreases in ns-SELENA-SLEDAI scores, BILAG-2004 index scores and uPCR, and increases in all domains of SF-36 (p<0.01). The longitudinal decrease in ns-SELENA-SLEDAI and BILAG-2004 index scores was significantly associated with reduced EC4d and EC3d levels, reduced anti-C1q titres and increased serum complement C3/C4 (p<0.05). The changes in uPCR significantly correlated with C3, C4, anti-C1q and EC4d, with EC4d outperforming C3/C4 by a multivariate analysis. The reduced EC4d or EC3d was associated with improvements in at least six out of the eight domains of SF-36 and outperformed C3/C4. Anti-dsDNA titres did not correlate with changes in disease activity.ConclusionsThese data indicate that CB-CAPs and anti-C1q are helpful in monitoring patients with SLE
Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus
BACKGROUND: The relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated. METHODS: Per protocol, at baseline all SLE subjects enrolled in this longitudinal study presented with active disease and elevated CB-CAPs. At each monthly visit, the non-serological (ns) Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA-SLEDAI) and the British Isles Lupus Assessment Group (BILAG)-2004 index scores were determined as was a random urinary protein to creatinine ratio (uPCR). Short-form 36 (SF-36) questionnaires were also collected. All soluble markers were determined using immunoassays, while EC4d and EC3d were determined using flow cytometry. Statistical analysis consisted of linear mixed models with random intercept and fixed slopes. RESULTS: A total of 36 SLE subjects (mean age 34 years; 94% female) were enrolled and evaluated monthly for an average 11 visits per subject. Clinical improvements were observed during the study, with significant decreases in ns-SELENA-SLEDAI scores, BILAG-2004 index scores and uPCR, and increases in all domains of SF-36 (p<0.01). The longitudinal decrease in ns-SELENA-SLEDAI and BILAG-2004 index scores was significantly associated with reduced EC4d and EC3d levels, reduced anti-C1q titres and increased serum complement C3/C4 (p<0.05). The changes in uPCR significantly correlated with C3, C4, anti-C1q and EC4d, with EC4d outperforming C3/C4 by a multivariate analysis. The reduced EC4d or EC3d was associated with improvements in at least six out of the eight domains of SF-36 and outperformed C3/C4. Anti-dsDNA titres did not correlate with changes in disease activity. CONCLUSIONS: These data indicate that CB-CAPs and anti-C1q are helpful in monitoring patients with SLE
Recommended from our members
Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus.
BackgroundThe relationship between cell-bound complement activation products (CB-CAPs: EC4d, EC3d), anti-C1q, soluble complement C3/C4 and disease activity in systemic lupus erythematosus (SLE) was evaluated.MethodsPer protocol, at baseline all SLE subjects enrolled in this longitudinal study presented with active disease and elevated CB-CAPs. At each monthly visit, the non-serological (ns) Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA-SLEDAI) and the British Isles Lupus Assessment Group (BILAG)-2004 index scores were determined as was a random urinary protein to creatinine ratio (uPCR). Short-form 36 (SF-36) questionnaires were also collected. All soluble markers were determined using immunoassays, while EC4d and EC3d were determined using flow cytometry. Statistical analysis consisted of linear mixed models with random intercept and fixed slopes.ResultsA total of 36 SLE subjects (mean age 34 years; 94% female) were enrolled and evaluated monthly for an average 11 visits per subject. Clinical improvements were observed during the study, with significant decreases in ns-SELENA-SLEDAI scores, BILAG-2004 index scores and uPCR, and increases in all domains of SF-36 (p<0.01). The longitudinal decrease in ns-SELENA-SLEDAI and BILAG-2004 index scores was significantly associated with reduced EC4d and EC3d levels, reduced anti-C1q titres and increased serum complement C3/C4 (p<0.05). The changes in uPCR significantly correlated with C3, C4, anti-C1q and EC4d, with EC4d outperforming C3/C4 by a multivariate analysis. The reduced EC4d or EC3d was associated with improvements in at least six out of the eight domains of SF-36 and outperformed C3/C4. Anti-dsDNA titres did not correlate with changes in disease activity.ConclusionsThese data indicate that CB-CAPs and anti-C1q are helpful in monitoring patients with SLE
Recommended from our members
A homeostatic model of IkappaB metabolism to control constitutive NF-kappaB activity.
Cellular signal transduction pathways are usually studied following administration of an external stimulus. However, disease-associated aberrant activity of the pathway is often due to misregulation of the equilibrium state. The transcription factor NF-kappaB is typically described as being held inactive in the cytoplasm by binding its inhibitor, IkappaB, until an external stimulus triggers IkappaB degradation through an IkappaB kinase-dependent degradation pathway. Combining genetic, biochemical, and computational tools, we investigate steady-state regulation of the NF-kappaB signaling module and its impact on stimulus responsiveness. We present newly measured in vivo degradation rate constants for NF-kappaB-bound and -unbound IkappaB proteins that are critical for accurate computational predictions of steady-state IkappaB protein levels and basal NF-kappaB activity. Simulations reveal a homeostatic NF-kappaB signaling module in which differential degradation rates of free and bound pools of IkappaB represent a novel cross-regulation mechanism that imparts functional robustness to the signaling module